We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: AI

Revolutionizing Cardiac Rehab: The Impact of Wearable Technology and Online Coaching

MedXY Editorial Team•Oct 23, 2025•AI
coronary artery diseaseremote monitoringwearable technology

Introduction

Cardiac rehabilitation (CR) is a cornerstone of secondary prevention in patients with coronary artery disease (CAD), significantly reducing morbidity and mortality through structured exercise programs, lifestyle counseling, and risk factor management. Despite its proven benefits, participation rates remain suboptimal due to logistical barriers, such as transportation issues, scheduling conflicts, and geographic limitations. Innovations in digital health, particularly wearable devices combined with telehealth strategies, have shown promise in overcoming these barriers and expanding access to CR.

This article critically examines a recent randomized controlled trial (RCT) that assessed the efficacy of a remote CR program integrating wearable technology and real-time monitoring, with or without weekly online coaching (OLC), aiming to improve exercise capacity in patients with CAD.

Study Background

The burden of CAD, the leading cause of cardiovascular mortality worldwide, underscores the importance of effective secondary prevention strategies such as CR. Traditional center-based CR programs are underutilized, prompting interest in home-based and remote alternatives. Wearable devices have the potential to facilitate continuous activity monitoring and personalized feedback, promoting adherence and safety. Yet, evidence from rigorous trials evaluating their efficacy, especially in conjunction with online coaching, has been limited.

Study Design

This phase III, open-label, single-center pilot RCT enrolled 50 patients with diagnosed CAD. Following baseline cardiopulmonary exercise testing (CPET), all participants were provided a wearable device (Fitbit Sense) and a real-time monitoring system (Recoval). The participants were randomized 1:1 into two groups:

1. Intervention group with weekly online coaching (OLC)
2. Control wearable device group without OLC

Both groups undertook a CPET-based home exercise program tailored to their individual functional capacity, aiming to improve exercise tolerance over 12 weeks. Primary endpoints focused on changes in peak oxygen consumption (peak VO2) and anaerobic threshold VO2. Secondary outcomes included other CPET parameters, daily activity levels, anxiety and depression scores, and health-related quality of life (HRQoL).

Key Findings

The study revealed significant improvements in exercise capacity in both groups after 12 weeks. Specifically, peak VO2 increased by an average of 1.6 mL/kg/min in the OLC group (P<.001) and by 0.6 mL/kg/min in the control group (P=.008). Similar trends were observed for anaerobic threshold VO2, with no statistically significant differences between the groups (P=.65 for peak VO2; P=.90 for anaerobic threshold).

Notably, during the latter half of the intervention, participants in the OLC group significantly increased their daily walking distance and the time spent in high-activity levels compared to controls (both P<.05). These findings suggest that while both groups experienced improved exercise capacity, weekly online coaching further enhanced physical activity, especially at higher intensities.

Mental health assessments and HRQoL scores showed no significant differences between groups, indicating that the intervention was well tolerated. No major adverse cardiac events or safety issues were reported, aside from one dropout due to lower limb muscle strain.

Discussion and Implications

This study demonstrates that remote CR leveraging wearable technology and real-time data monitoring can effectively improve exercise capacity in patients with CAD. Importantly, the addition of weekly online coaching appears to augment physical activity levels, particularly in higher-intensity activities, which are critical for cardiovascular health.

The findings support integrating wearable device-enabled telehealth strategies into routine cardiac care to increase accessibility and adherence. However, larger studies over longer durations are necessary to confirm these benefits and evaluate impacts on clinical outcomes such as cardiovascular events, hospitalization rates, and long-term mortality.

Limitations of this study include its small sample size, single-center design, and relatively short follow-up period. Future research should explore optimal coaching frequency, patient engagement strategies, and cost-effectiveness analyses to facilitate broad implementation.

Conclusion

The trial provides promising evidence that remote cardiac rehabilitation with wearable devices and real-time monitoring can significantly enhance exercise capacity in CAD patients. Weekly online coaching further boosts activity levels, especially at higher intensities. These innovations hold potential to transform secondary prevention, making CR more accessible, personalized, and effective.

Colorful integration of digital health tools into cardiac care pathways should be prioritized, with future studies addressing long-term outcomes and diverse patient populations to maximize their clinical impact.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention ApproachThis review synthesizes emerging evidence from the PROACT trials on genotype-first identification of subclinical coronary atherosclerosis using polygenic risk scores (PRS), highlighting feasibility, engagement, and high prevalence of silentSep 15, 2026Linking Air Pollution to Heart Health: Chronic PM2.5 Exposure and Coronary Endothelial DysfunctionChronic exposure to fine particulate matter (PM2.5) is linked to epicardial coronary endothelial dysfunction, an early marker of coronary artery disease, as demonstrated by invasive coronary vasoreactivity testing.Sep 11, 2026Long-Term Benefits of Quantitative Flow Ratio-Guided PCI: Insights from the 5-Year FAVOR III China TrialThe FAVOR III China trial demonstrates that QFR-guided percutaneous coronary intervention significantly reduces major adverse cardiac events over 5 years, mainly by decreasing myocardial infarction and ischemia-driven revascularization compSep 11, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
suPAR as a Novel Marker for Residual Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes with Coronary Artery Disease
In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR&#8217;s potential in identifying treatment-r
Aug 21, 2026
Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical ImplicationsEmerging evidence identifies circulating imidazole propionate, a gut microbiota-derived metabolite, as an independent predictor of major adverse cardiovascular events in patients with coronary artery disease, offering novel insights into peAug 18, 2026
Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 TrialThe TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year followJul 2, 2026